Culture Biosciences, a frontrunner in cloud-based biomanufacturing, has successfully closed its Series C funding round. Announced on December 16, 2025, the round was spearheaded by existing investors, including Northpond Ventures, Synthesis Capital, S32, and Cultivian Sandbox. This significant investment underscores the confidence that shareholders have in Culture’s growth trajectory and long-term strategy.
The Series C financing will primarily support the commercial expansion of Culture’s innovative hardware product, the Stratyx 250. This state-of-the-art system is designed to offer scalable, automated, and digitally connected bioprocessing capabilities. It caters to the evolving needs of modern biologics, cell therapy, and advanced bioprocess development.
In addition to hardware advancements, the funding will also enhance the ongoing development of Culture’s AI-powered Console software ecosystem. This software is integral to maximizing the effectiveness and efficiency of biomanufacturing processes, providing users with valuable insights and operational controls.
Culture Biosciences has positioned itself at the forefront of the biomanufacturing industry by leveraging cloud technology to meet the complex demands of today’s market. The company aims to streamline production processes, making them more accessible and efficient for a variety of applications.
The successful completion of the Series C round highlights a growing trend in the biotech sector, where investment in innovative technologies is crucial for maintaining competitive advantage. As the industry evolves, companies like Culture Biosciences are poised to play a significant role in shaping the future of biomanufacturing.
This funding round not only reflects shareholder confidence but also marks a pivotal moment for Culture as it seeks to accelerate growth and enhance its product offerings. With the backing of prominent investors, the company is well-positioned to further its mission and expand its market presence.
